-
Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine; PDUFA goal date is January 31 2025
NASDAQ: $AXSM Axsome Therapeutics, a leading biopharmaceutical company, has recently announced the exciting news that the U.S. Food and Drug Administration (FDA) has accepted the resubmission of the New Drug Application (NDA) for AXS-07 for the acute treatment of migraine. With the FDA acceptance of the NDA resubmission, Axsome Therapeutics is one step closer to…
-
Riding the Waves: S&P 500 Performance in Election Years
When you think about the stock market, especially the S&P 500, you might wonder how politics plays into the mix. Election years often stir up a whirlwind of emotions, debates, and strategies. But how does this affect one of the most followed stock indices in the U.S.? Let’s dive into how the S&P 500 performs…
-
Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolR?-targeted ADC, on January 4, 2024
NASDAQ: $STRO 1. Introduction to Sutro Biopharma’s Investor Webcast Welcome to the article covering the upcoming investor webcast hosted by Sutro Biopharma on January 4, 2024. This webcast aims to highlight the potential multi-cancer opportunity associated with Luvelta, a promising FolR?-targeted Antibody-Drug Conjugate (ADC) developed by Sutro Biopharma. In this article, we will delve into…
-
Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines
NASDAQ: $CGEM 1. Introduction to CLN-617: A Novel Fusion Protein The field of oncology research continues to evolve with the aim of developing innovative and effective therapies to combat cancer. In this regard, Cullinan Oncology has recently announced the initiation of a Phase 1 clinical trial to evaluate the potential of CLN-617, a novel fusion…
-
BIO-TECH STOCK CATALYST REPORT FOR WEEK OF DECEMBER 10-16, 2023
December 10, 2023 EVENT EVENT DATE SYMBOL PRICE POTENTIAL % (+/-) OPEN INTEREST PRICE Conference 12/10/2023 AUTL 21.1 4,281 $4.36 Conference 12/10/2023 BLUE 26.9 18,165 $2.86 Conference 12/10/2023 BMEA 43.0 49,731 $16.89 Announcement 12/11/2023 COGT 28.9 11,224 $8.64 Conference 12/11/2023 BLUE 26.9 18,165 $2.86 Conference 12/11/2023 HARP 35.3 295 $8.94 Conference 12/14/2023 BCYC 24.0 2,878…
-
Actinium | Highlights Broad Potential of Targeted Radiotherapies Iomab-B and Actimab-A for Relapsed or Refractory and Elderly Acute Myeloid Leukemia Patients at the 65th ASH Annual Meeting & Exposition
NYSE: $ATNM NEW YORK, Dec. 8, 2023 /PRNewswire/ — Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: $ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that clinical data from its Iomab-B and Actimab-A programs will be featured in four presentations at the 65th Annual American Society of Hematology Annual Meeting &…
-
Kura Oncology | Menin Inhibitor Ziftomenib Selected for The Leukemia & Lymphoma Society’s Pediatric Acute Leukemia (PedAL) Master Clinical Trial
NASDAQ: $KURA SAN DIEGO, Dec. 08, 2023 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (NASDAQ: $KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, and The Leukemia & Lymphoma Society (LLS), the largest private funder of blood cancer research, today announced a clinical collaboration to evaluate Kura’s…
-
BD Receives FDA 510(k) Clearance for Potentially Transformative Fingertip Blood Collection Device
NYSE: $BDX 1. Introduction: Overview of BD’s FDA 510(k) Clearance for Potentially Transformative Fingertip Collection Device The field of sample collection in healthcare is about to witness a significant transformation with the recent FDA 510(k) clearance obtained by BD for their groundbreaking fingertip collection device. This innovative device offers a convenient and user-friendly alternative to…
-
Curis Announces Three Presentations at ASH
NASDAQ: $CRIS LEXINGTON, Mass., Dec. 6, 2023 /PRNewswire/ — Curis, Inc. (NASDAQ: $CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company along with its collaborative partners will be presenting three posters at the upcoming 65th ASH Annual Meeting and Exposition (ASH…
-
Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer’s
NASDAQ: $SNPX 1. Introduction: Synaptogenix’s participation in USC-Sponsored Forum on Age-Related Diseases Synaptogenix, a renowned leader in the field of neurology and Alzheimer’s research, is set to join a distinguished group of neuroscientists and academics as a speaker at the USC-Sponsored Forum on Age-Related Diseases. This eagerly anticipated event aims to delve into the latest…
-
Anixa Biosciences and Cleveland Clinic Present Positive New Data from Phase 1 Study of Breast Cancer Vaccine
NASDAQ: ANIX 1. Introduction to Anixa Biosciences and Cleveland Clinic collaboration Anixa Biosciences: A leading biotechnology company Cleveland Clinic: A renowned medical center Anixa Biosciences, a prominent biotechnology company, has joined forces with Cleveland Clinic, a renowned medical center, to present the exciting new data from a Phase 1 study of their innovative cancer vaccine.…
-
Allarity’s Early Phase 2 Stenoparib Data Indicates Clinical Benefit in Women with Advanced Ovarian Cancer Selected with DRP® Companion Diagnostic
NASDAQ: ALLR 1. Introduction to Allarity’s Early Phase 2 Stenoparib Data The field of oncology continues to witness groundbreaking advancements in precision medicine, with targeted therapies revolutionizing the treatment landscape for various cancers. In this context, Allarity, a leading biotechnology company, has recently released early phase 2 data showcasing the potential clinical benefit of their…
-
Calliditas Therapeutics | The FDA Decision To Convert The Accelerated Approval of Calliditas Therapeutics’ Tarpeyo To Full Approval, December 20, 2023
NASDAQ: CALT 1. Introduction to Calliditas Therapeutics and Tarpeyo Calliditas Therapeutics is a renowned pharmaceutical company focused on developing innovative therapies to address unmet medical needs. One of their notable products is Tarpeyo, a drug designed to provide significant benefits to patients suffering from a specific medical condition. The accelerated approval granted by the FDA…
-
KALA BIO | Stock Price Up Today 43%+, Get Ready For A Move
NASDAQ: KALA Introduction to KALA BIO and its recent stock performance Investors and traders have been closely monitoring the recent surge in KALA BIO’s stock price, which has seen a remarkable 43% increase. KALA BIO, a pharmaceutical company focused on developing innovative therapies, has captured the attention of the market with its promising advancements. In…
-
Vanda Pharmaceuticals | Announces U.S. FDA Accepts New Drug Application for Tradipitant for the Treatment of Gastroparesis
NASDAQ: VNDA 1. Introduction to Vanda Pharmaceuticals’ new drug application for Tradipitant Vanda Pharmaceuticals, a leading biopharmaceutical company, has recently announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) for Tradipitant, a potential breakthrough treatment for gastroparesis. This acceptance marks a significant milestone in Vanda Pharmaceuticals’ efforts…
-
NeuroSense | Reporting Phase 2b ALS Topline Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints on December 5, 2023
NASDAQ: NRSN Introduction NeuroSense, a groundbreaking biopharmaceutical company, is set to release the highly anticipated topline results of its Phase 2b clinical trial for ALS (Amyotrophic Lateral Sclerosis) on December 5, 2023. This milestone event marks a significant step forward in the search for new treatment options for this devastating disease. In this article, we…
-
RxE2 | Revolutionizes Clinical Trials with Groundbreaking AI-led Technology Platform and Marketplace
Introduction In the world of medical advancements, clinical trials play a crucial role in testing new drugs, treatments, and procedures to ensure their safety and efficacy. However, the traditional approach to conducting clinical trials is often time-consuming, costly, and resource-intensive. Enter RxE2, an innovative technology platform and marketplace that is revolutionizing the way clinical trials…
-
IDEAYA | Announces Agenda for Investor R&D Day Webcast on December 4, 2023
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company dedicated to the discovery and development of targeted therapeutics, is pleased to announce the agenda topics for its upcoming Investor R&D Day. This highly anticipated webcast event, hosted by IDEAYA, will take place on Monday, December 4, 2023, from 8:00 am to 9:30 am…
-
BIO-TECH STOCK CATALYST REPORT FOR WEEK OF DECEMBER 3-9, 2023
December 2, 2023 EVENT EVENT DATE SYMBOL PRICE POTENTIAL % (+/-) OPEN INTEREST PRICE Conference 12/05/2023 JAGX 27.4 9,151 $0.36 Conference 12/07/2023 BMEA 43.2 25,780 $16.68 FDA Event 12/08/2023 BCLI 52.0 5,135 $0.26 Conference 12/09/2023 APTO 32.4 76 $2.66 Conference 12/09/2023 INCY 27.1 38,201 $54.02 WEEK: 12/03/2023 – 12/09/2023
-
Neurocrine Biosciences | Hosting Analyst Day on December 5, 2023
NASDAQ: $NBIX Neurocrine Biosciences to Host Analyst Day on December 5, 2023 Have you heard the news? Neurocrine Biosciences, a leading biopharmaceutical company, is set to host an Analyst Day on December 5, 2023. This highly anticipated event will bring together analysts, investors, and industry experts to explore Neurocrine Biosciences’ latest developments and future prospects.…
-
Intensity Therapeutics | Selected for Spotlight Oral Presentation at the 2023 San Antonio Breast Cancer Symposium
NASDAQ: INTS Intensity Therapeutics, a biotechnology company dedicated to developing innovative cancer therapies, has been selected to present at the prestigious Spotlight Oral Presentations. This recognition highlights the immense potential of the company’s scientific breakthroughs and further establishes its position as a leader in the field of oncology research. The selection also underscores the intelligence…
-
NeuroBo | Participating in Investor Conferences in December
NASDAQ: NRBO NeuroBo, a clinical-stage biotechnology company specializing in treatments for neurodegenerative diseases, has recently announced that it will be attending several investor conferences during the month of December. This move represents an exciting opportunity for the company to showcase its groundbreaking research and attract potential investors. With a focus on developing novel therapeutics for…
-
Jaguar Health | Presents December 5 at the MedInvest Oncology Investor Conference
Jaguar Health, a leading pharmaceutical company specializing in innovative treatments for various diseases, is set to present at the prestigious MedInvest Oncology Investor Conference on December 5. This highly anticipated event brings together top experts, investors, and industry leaders in the field of oncology. Jaguar Health’s participation at this conference is a testament to their…
-
Soligenix | Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in the Treatment of Aphthous Ulcers in Behçet’s Disease
NASDAQ: SNGX Introduction to Soligenix’s Phase 2 Clinical Trial Soligenix, a biopharmaceutical company focused on developing innovative therapies, has recently received FDA Investigational New Drug (IND) clearance for the Phase 2 clinical trial of Dusquetide in the treatment of aphthous ulcers in Behçets Disease. This clearance marks a significant milestone in the development of potential…
-
Carisma Therapeutics | Announces FDA Clearance of IND Application for CT-0525, a Novel HER2-Targeting CAR-Monocyte
NASDAQ: CARM Carisma Therapeutics, a leading biotechnology company committed to developing innovative cancer treatments, recently made a groundbreaking announcement. The company has successfully obtained clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application. This is a significant milestone for Carisma Therapeutics, as it paves the way for the…